Printer Friendly

Printed from http://www.researchandmarkets.com/reports/2152223

Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022

Description:
Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022

Summary

GlobalData’s pharmaceuticals report, “Gammagard Liquid (Alzheimer’s disease) – Analysis and Forecasts to 2022” provides Gammagard Liquid global sales estimates. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2022). The report also includes information on Alzheimer's disease market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US and EU5 (six major markets)
- Analysis and review of Gammagard Liquid including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Gammagard Liquid including efficacy, safety, pricing, competition and other details which influence its sales potential
- Global sales forecast for 2014-2022 for Gammagard Liquid

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2022 for all seven major markets

Keywords

Gammagard Liquid, Kiovig, Immune Globulin Intravenous (Human) 10%, Baxter, Alzheimer’s disease, dementia
 
Contents:
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Alzheimer’s disease
2.2 Symptoms
2.3 Alzheimer’s disease Market
2.4 Epidemiology
2.5 Etiology
2.5.1 Age
2.5.2 Family History
2.5.3 Genetics
2.6 Economic Impact of Alzheimer’s disease
2.7 GlobalData Report Guidance
3 Alzheimer’s disease: Market Characterization
3.1 Alzheimer’s disease Market
3.2 Alzheimer’s disease Market Forecasts and CAGR
3.3 Drivers and Barriers of Alzheimer’s disease Therapeutics Market
3.3.1 Ageing Population
3.3.2 Patent Expiries
3.3.3 New Product Launches
3.3.4 High Unmet Need
4 Classification of Alzheimer’s disease
4.1 Stage 1 (Mild)
4.2 Stage 2 (Moderate)
4.3 Stage 3 (Severe)
5 Treatment for Alzheimer’s disease
5.1 Cognitive Symptoms
5.1.1 Cholinesterase Inhibitors (ChEIs)
5.1.2 NMDA antagonists
5.1.3 Other Pharmacotherapeutic Agents
5.2 Behavioural Symptoms and Mood Disorders
5.2.1 Non-pharmacological Approaches
5.2.2 Prescription Medicines
5.3 Next-generation Drugs
5.3.1 Disease Modifying Agents
5.3.2 Tau-directed Therapies
5.3.3 Other Therapies
6 Gammagard Liquid
6.1 Introduction
6.2 Mechanism of Action
6.3 Clinical Studies
6.3.1 A Placebo-controlled, Randomized, Double-Blind Phase II Clinical Study of Gammagard Intravenous Immunoglobulin (IVIG) for Treatment of Mild to Moderate Alzheimer’s disease
6.3.2 A Phase III Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild to Moderate Alzheimer´s Diseases
6.4 Factors Affecting Sales of Gammagard Liquid
6.4.1 Anti Amyloid Drug with Disease Halting Potential
6.4.2 First in Class
6.4.3 Superior efficacy of Gammagard Liquid
6.4.4 Patent Expiry of Existing Marketed Drugs
6.4.5 Competition with Pipeline Drugs
6.5 Drug Evaluation
6.5.2 Intensity of Competition
6.6 Sales Forecast
6.6.1 Target Patient Pool for Gammagard Liquid
6.6.2 Dosing
6.6.3 Market Penetration
6.6.4 Sales Projections of Gammagad Liquid
7 Appendix
7.1 Market Definitions
7.2 Abbreviations
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Number of Patients Approved to Take the Drug
7.3.5 Net Penetration of Drug
7.3.6 Net Annual Dosing
7.3.7 Annual Cost of Therapy
7.4 Drug Sales Estimates Model
7.5 Contact Us
7.6 Disclaimer
7.7 Sources

1.1 List of Tables
Table 1: Alzheimer’s disease, World, Major Pipeline Products in Phase III
Table 2: Mild Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 3: Moderate Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 4: Severe Stage Alzheimer’s disease, Abilities Affected and Their Typical Symptoms
Table 5: Non-pharmacological Approaches for Behavioural Symptoms and Mood Disorders
Table 6: Experimental Disease Modifying Drugs in Phase III for Alzheimer’s disease
Table 7: Gammagard Liquid, Phase II, Clinical Trial Results
Table 8: Gammagard Liquid, Alzheimer’s disease, Drug Risk Benefit Score
Table 9: Gammagad Liquid, Alzheimer’s disease, Global, Sales Forecasts ($m), 2014–2022
Table 10: Gammagard Liquid, Alzheimer’s disease, The US, Sales Forecasts ($m), 2014–2022
Table 11: Gammagard Liquid, Alzheimer’s disease, UK, Sales Forecasts ($m), 2015–2022
Table 12: Gammagard Liquid, Alzheimer’s disease, France, Sales Forecasts ($m), 2015–2022
Table 13: Gammagard Liquid, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2015–2022
Table 14: Gammagard Liquid, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2015–2022
Table 15: Gammagard Liquid, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2015–2022

1.2 List of Figures
Figure 1: Brain Affected by Alzheimer’s disease
Figure 2: Estimated Lifetime Risks for Alzheimer’s by Age and Sex, The US
Figure 3: Estimated Number of Cases of Alzheimer’s disease (in million), The US
Figure 4: Changes in Selected Causes of Death, The US, 2000-2008
Figure 5: Alzheimer’s disease, Global, Market Size Forecasts ($bn), 2011–2022
Figure 6: Drug Model Diagram of Gammagard Liquid
Figure 7: Gammagad Liquid, Alzheimer’s disease, Global, Sales Forecasts ($m), 2014–2022
Figure 8: Gammagard Liquid, Alzheimer’s disease, The US, Sales Forecasts ($m), 2014–2022
Figure 9: Gammagard Liquid, Alzheimer’s disease, UK, Sales Forecasts ($m), 2015–2022
Figure 10: Gammagard Liquid, Alzheimer’s disease, France, Sales Forecasts ($m), 2015–2022
Figure 11: Gammagard Liquid, Alzheimer’s disease, Germany, Sales Forecasts ($m), 2015–2022
Figure 12: Gammagard Liquid, Alzheimer’s disease, Italy, Sales Forecasts ($m), 2015–2022
Figure 13: Gammagard Liquid, Alzheimer’s disease, Spain, Sales Forecasts ($m), 2015–2022
Figure 14: Gammagard Liquid, Alzheimer’s disease, Sales Distribution by Country (%), 2022
Figure 15: Patients Approved for the Drug
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/2152223

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Nov 27, 2014
12:45:29 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Gammagard Liquid (Alzheimer's disease) - Analysis and Forecasts to 2022

Web Address

http://www.researchandmarkets.com/reports/2152223

Office Code

SCOI7T

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License USD 4,000
Electronic (PDF) - Single User USD 2,000
Electronic (PDF) - Enterprisewide USD 6,000

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Nov 27, 2014
12:45:29 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)